Genmab A/s

(NASDAQ) GMAB

Current Price$26.36

Market Cap$16.12B

Since IPO (2013)+656%

5 Year-26%

1 Year+36%

1 Month-4%

Genmab A/s Financials at a Glance

Market Cap

$16.12B

Revenue (TTM)

$8.84B

Net Income (TTM)

$2.61B

EPS (TTM)

$1.33

P/E Ratio

20.23

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$26.36

Volume

37,081

Open

$26.52

Price

$26.36

Volume

37,081

Open

$26.52

Previous Close

$27.09

Daily Range

$26.37 - $26.77

52-Week Range

$19.05 - $35.43

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$26.36

Volume

37,081

Open

$26.52

Previous Close

$27.09

Daily Range

$26.37 - $26.77

52-Week Range

$19.05 - $35.43

GMAB News

Person checking medicine on a shelf in a pharmacy

Are There Good Investments Among 2019's Biotech IPOs?

David HaenOct 2, 2019

GMAB: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genmab A/s

Industry

Biotechnology

Sector

Health Care

Employees

3,088

CEO

Jan G. J. van de Winkel, PhD

Website

www.genmab.com

Headquarters

Copenhagen, 1560, DK

GMAB Financials

Key Financial Metrics (TTM)

Gross Margin

94%

Operating Margin

40%

Net Income Margin

18%

Return on Equity

15%

Return on Capital

51%

Return on Assets

21%

Earnings Yield

4.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$16.12B

Shares Outstanding

594.91M

Volume

37.08K

Avg. Volume

1.78M

Financials (TTM)

Gross Profit

$3.41B

Operating Income

$1.25B

EBITDA

$1.32B

Operating Cash Flow

$1.19B

Capital Expenditure

$37.03M

Free Cash Flow

$1.15B

Cash & ST Invst.

$1.71B

Total Debt

$5.43B

Genmab A/s Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$899.32M

+25.8%

Gross Profit

$834.08M

+23.9%

Gross Margin

92.75%

N/A

Market Cap

$16.12B

N/A

Market Cap/Employee

$6.11M

N/A

Employees

2,638

N/A

Net Income

$53.20M

-72.7%

EBITDA

$225.83M

-14.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$3.83B

-122.0%

Accounts Receivable

$1.03B

-83.7%

Inventory

$21.00M

-74.5%

Long Term Debt

$5.06B

+504.7%

Short Term Debt

$293.00M

+189.0%

Return on Assets

21.14%

N/A

Return on Invested Capital

50.76%

N/A

Free Cash Flow

$2.01M

-100.1%

Operating Cash Flow

$3.01M

-99.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ZBHZimmer Biomet Holdings, Inc.

ZBHZimmer Biomet Holdings, Inc.$83.52+0.18%

THCTenet Healthcare Corporation

THCTenet Healthcare Corporation$195.50-0.19%

SMMTSummit Therapeutics Inc.

SMMTSummit Therapeutics Inc.$18.56-2.06%

INCYIncyte Corporation

INCYIncyte Corporation$97.43-1.71%

EXELExelixis, Inc.

EXELExelixis, Inc.$50.24+1.59%

ROIVRoivant Sciences Ltd.

ROIVRoivant Sciences Ltd.$28.95-1.51%

DGXQuest Diagnostics Incorporated

DGXQuest Diagnostics Incorporated$188.02-1.14%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$16.87+0.06%

NIONio

NIONio$6.52+0.07%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.70-0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.02+0.01%

RXTRackspace Technology

RXTRackspace Technology$5.96-0.06%

NVDANvidia

NVDANvidia$227.29+0.03%

EOSEEos Energy Enterprises

EOSEEos Energy Enterprises$9.25+0.14%

Questions About GMAB

What is the current price of Genmab A/s?

Genmab A/s is trading at $26.39 per share.

What is the 52-week range for Genmab A/s?

Over the past 52 weeks, Genmab A/s has traded between $19.05 and $35.43.

How much debt does Genmab A/s have?

As of the most recent reporting period, Genmab A/s reported total debt of $5.35B.

How much cash does Genmab A/s have on hand?

Genmab A/s reported $1.52B in cash and cash equivalents in its most recent financial results.

What is Genmab A/s’s dividend yield?

Genmab A/s does not currently have a dividend yield.

Genmab A/s

Genmab A/s Financials at a Glance

GMAB News

Why Genmab Stock Popped on Friday

Why Genmab Stock Was Marching Higher Today

Why Genmab Stock Smashed It on Monday

Genmab Revenue Surges 18% in Q3

AbbVie Signs $3.9 Billion Oncology Deal with Genmab

Are There Good Investments Among 2019's Biotech IPOs?

GMAB: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Genmab A/s

GMAB Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Genmab A/s Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About GMAB

What is the current price of Genmab A/s?

What is the 52-week range for Genmab A/s?

How much debt does Genmab A/s have?

How much cash does Genmab A/s have on hand?

What is Genmab A/s’s dividend yield?

Premium Investing Services